TriSalus Life Sciences, Inc. Interest Expense
TriSalus Life Sciences, Inc. (TLSI) reported Interest Expense of $877.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-08-14
- TriSalus Life Sciences, Inc. interest expense for the quarter ending 2024-06-30 was $877.00K, a 21825.00% increase year-over-year.
- TriSalus Life Sciences, Inc. interest expense for the quarter ending 2024-03-31 was $3.00K, a 40.00% decline year-over-year.
- TriSalus Life Sciences, Inc. interest expense for the quarter ending 2023-12-31 was $3.00K, a 200.00% increase year-over-year.
- TriSalus Life Sciences, Inc. interest expense for the quarter ending 2023-09-30 was $4.00K.
- TriSalus Life Sciences, Inc. interest expense for fiscal 2023 was $16.00K, a 1500.00% increase from fiscal 2022.
- TriSalus Life Sciences, Inc. interest expense for fiscal 2022 was $1.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $877.00K 10-Q · filed 2024-08-14 | $880.00K 10-Q · filed 2024-08-14 | $883.00K derived: sum of 3 quarters · filed 2024-08-14 | $887.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | $3.00K 10-Q · filed 2024-05-15 | $6.00K derived: sum of 2 quarters · filed 2024-05-15 | $10.00K derived: sum of 3 quarters · filed 2024-05-15 | $14.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $7.00K derived: sum of 2 quarters · filed 2024-04-11 | $11.00K derived: sum of 3 quarters · filed 2024-08-14 | $16.00K 10-K · filed 2024-04-11 |
| 2023-09-30 | $4.00K 10-Q · filed 2023-11-14 | $8.00K derived: sum of 2 quarters · filed 2024-08-14 | $13.00K 10-Q · filed 2023-11-14 | $14.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-06-30 | $4.00K 10-Q · filed 2024-08-14 | $9.00K 10-Q · filed 2024-08-14 | $10.00K derived: sum of 3 quarters · filed 2024-08-14 | $10.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $5.00K 10-Q · filed 2024-05-15 | $6.00K derived: sum of 2 quarters · filed 2024-05-15 | $6.00K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $1.00K derived: sum of 2 quarters · filed 2024-04-11 | $1.00K 10-K · filed 2024-04-11 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |